- Novartis AG’s (NYSE:NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL).
- The BELINDA study included patients after relapse or lack of response to first-line treatment.
- The safety profile was consistent with the established safety profile of Kymriah.
- Novartis will complete a full evaluation of the BELINDA study data.
- Price Action: NVS shares are down 1.05% at $92.77 during the premarket session on the last check Tuesday.
Toll Brothers Campus Living Unit Reports Formation Of Joint Venture With CanAm Enterprises To Develop 293-Unit Student Housing Community In Miami, Florida
Toll Brothers, Inc. (NYSE:TOL) (www.TollBrothers.com), the nation’s leading builder of luxury homes, through its Toll Brothers Campus Living division, and CanAm Capital Partners, the private-equity affiliate of
